Co-Diagnostics Expands Vector Control Customer Base To 25 Customers Across 15 U.S. States, Following An Installation In Nevada Next Week

Co-Diagnostics, Inc. (NASDAQ:CODX) (the "Company" or "Co-Dx™"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that use of the Company's vector control technology will expand to the 15th U.S. state following an installation in Nevada next week.

Co-Dx vector control technology includes Vector Smart® PCR tests used in environmental (non-diagnostic) surveillance of mosquito pools for mosquito-borne illnesses like West Nile virus, Zika, dengue and chikungunya. Mosquito abatement districts (MADs) and other vector control customers can use Vector Smart tests as well as other equipment sold and installed by Co-Diagnostics to receive same-day results of mosquito pool testing, allowing for quicker and more efficient prevention of disease transmission to humans and animals.